The business objective of Axiogenesis lies in the area of pre-clinical biotechnology, specifically in the development and production of stem cell-derived cell types (e.g. cardiac & neuronal cells) and cell-based assays that enable drug development. Axiogenesis cells and assays facilitate increased drug development efficiency at lower costs, driven by 1) increased physiological relevance of screening models, resulting in reduced attrition of late stage drug candidates; and 2) partial substitution of costly and ethically questionable animal studies.
View the Axiogenesis profile in European Biotechnology (2014).
This range of products has been further developed employing groundbreaking human induced PluripotentStem cell (iPS) technology. Through licensing of the well-known "Yamanaka factors" (iPS Academia, 2010), as well as in-house specialization of human iPS technology, Axiogenesis is capturing the true promise of stem cell biology by bringing human cells & tissue to the marketplace in a scalable, reproducible and cost-effective manner.
With iPS technology it is possible to "re-program" (or de-differentiate) adult human cells (e.g., skin or blood cells) to an artificial embryonic-like state. Using proprietary technology, Axiogenesis then forward-differentiates these into pure organ-specific cells and defined tissues. The first human, organ-specific iPS cells were launched in 2012 (Cor.4U@ human cardiomyocytes), followed by human neuronal cell types (Peri.4UTM & Dopa.4UTM) in 2014 and further cardic ventricular cells (vCor.4UTM) and cardiac fibroblasts (FibroCor.4UTM) in 2015.
With the production of tissue models (e.g. cardiac, neuronal, hepatic, etc) through the proliferation and differentiation of human iPS cells, researchers can test the efficacy and potential adverse side effects of drug candidates.
Increased drug development efficiency, with the use of Axiogenesis technology, is achieved through:
- Earlier selections against drug candidates that will have high adverse side affects (e.g. toxicity, cardiac arrhythmia) or do not have a therapeutic effect.
- Early selection and fast tracking of drug candidates with high efficacy and low side effects.
- Greater translation to the clinic, reducing false-positive signals and moving more safe drugs through development.
- Partial substitution of costly animal studies.
- Reduction of the time taken for preclinical studies.
- Extension of marketing exclusivity gained through a shorter drug development cycle, resulting in a longer time from market authorization until patent protection is lost.
Furthermore the system lends itself to product line extension through rapid testing of side effect profiles and improvements in efficacy of modified compounds or through the identification of novel indications of existing active pharmaceutical ingredients (APIs).